Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Clasificación en acciones #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Precio por acción
$40.39
Última sincronización: 2023-08-18
Capitalización bursátil
$1.70B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Chinook Therapeutics, Inc. (KDNY)

Categoría

Historial del precio de la acción de Chinook Therapeutics, Inc. (KDNY)
Precio más alto de cierre: $40.34 el 2023-08-01

Precio más bajo de cierre: $177.63 el 2015-04-01
Historial del precio de la acción de Chinook Therapeutics, Inc. desde 2015 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.53 -12.48%
AU
$140.81 475.44%
US
$765.25 7.74%
CH